Actively Recruiting
Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2023-03-15
153
Participants Needed
1
Research Sites
195 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to investigate whether zoledronic acid-loaded bone cement (4mg ZOL+ gentamicin PMMA ) as adjuvant method can decrease local recurrence in patients with giant cell bone tumor following intralesional curettage surgery. The hypothesis is that patients with local administration of zoledronic acid to the bone cement has lower relapse rate compared those with traditional bone cement(gentamicin PMMA ).
CONDITIONS
Official Title
Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with primary resectable giant cell tumor of bone
- Lesion suitable for intralesional curettage with at least one intact bone column after tumor removal
- No previous treatment with systemic bisphosphonates or denosumab
- Expected survival longer than 18 months
- Signed informed consent form
You will not qualify if you...
- Patients with recurrent or extensive giant cell tumor unsuitable for curettage surgery
- Unexpected surgery at another center
- Surgery planned as revision rather than primary treatment
- Patients undergoing en-bloc or wide resection instead of curettage
- Inability to complete self-assessment during follow-up
- Difficulty completing full postoperative follow-up
- Previous use of bisphosphonate, zoledronic acid, or denosumab
- Participation in similar research projects
- Refusal to sign informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Zhejiang University
Hangzhou, China, 311200
Actively Recruiting
Research Team
M
Meng Liu, MD
CONTACT
K
Keyi Wang, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here